Y. Fernández

发表

Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

E. Esteban, J. Viéitez, A. Lacave, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials.

A. Lluch, I. Tusquets, Á. Rodríguez-Lescure, 2007, Cancer treatment reviews.

Finding the right dose of fulvestrant in breast cancer.

A. Lluch, I. Tusquets, I. Álvarez, 2013, Cancer treatment reviews.

Pegylated Liposomal Doxorubicin and Gemcitabine in a Fixed Dose Rate Infusion for the Treatment of Patients With Poor Prognosis of Recurrent Ovarian Cancer: A Phase Ib Study

E. Esteban, M. Sanmamed, M. Sierra, 2010, International Journal of Gynecologic Cancer.

Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain.

J. Garcia-conde, A. Lluch, V. Guillem, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: preliminary results of a phase II trial.

A. Lluch, V. Guillem, V. Carañana, 2000, Seminars in oncology.

Supportive care for patients with early breast cancer

A. Lluch, I. Tusquets, I. Álvarez, 2010, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Activity of carboplatin in patients with advanced non-small cell lung cancer pre-treated with a non-platinum combination

J. Viéitez, A. Lacave, Y. Fernández, 2005, Investigational New Drugs.

Cisplatin plus gemcitabine with or without vinorelbine as induction chemotherapy prior to radical locoregional treatment for patients with stage III non-small-cell lung cancer (NSCLC): results of a prospective randomized study.

E. Esteban, J. Viéitez, A. Lacave, 2007, Lung cancer.

Gemcitabine and vinorelbine (GV) versus cisplatin, gemcitabine and vinorelbine (CGV) as first-line treatment in advanced non small cell lung cancer: Results of a prospective randomized phase II study

E. Esteban, J. Viéitez, A. Lacave, 2006, Investigational New Drugs.

Activity of weekly irinotecan (CPT-11) in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes

E. Esteban, J. Viéitez, A. Lacave, 2003, Investigational New Drugs.

Novel therapeutic approaches to the treatment of metastatic breast cancer.

J. Cueva, A. de Juan, M. Ramos, 2010, Cancer treatment reviews.

Phase II, Multicenter, Single‐arm Trial of Eribulin as First‐line Therapy for Patients With Aggressive Taxane‐pretreated HER2‐Negative Metastatic Breast Cancer: The MERIBEL Study

M. Martínez-García, A. Llombart-Cussac, L. Calvo, 2019, Clinical breast cancer.

Breast cancer management in the elderly

J. Cueva, L. Calvo, S. Antolín, 2014, Clinical and Translational Oncology.

Development and validation of a sexual relations satisfaction scale in patients with breast cancer — “SEXSAT-Q”

M. Ramos, L. Calvo, M. Muñoz, 2019, Health and Quality of Life Outcomes.

Current controversies in the management of breast cancer

J. Albanell, A. Lluch, P. Gascón, 2010, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study

E. Esteban, M. Capelán, J. Viéitez, 2008, Investigational New Drugs.

Uracil and tegafur modulated with leucovorin

E. Espinosa, J. Feliu, J. Castro, 1997, Cancer.

Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias

E. Esteban, M. Sanmamed, J. Berros, 2010, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Evaluation of international treatment guidelines and prognostic tests for the treatment of early breast cancer.

A. Lluch, I. Tusquets, M. Margelí, 2008, Cancer treatment reviews.

Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of Spanish medical oncologists

J. Albanell, A. Lluch, A. de Juan, 2019, Journal of drug assessment.

Phase II study of mitomycin C plus 5-fluorouracil in patients with refractory ovarian cancer.

E. Esteban, R. López, A. Lacave, 1994, European Journal of Cancer.

Activity of topotecan given intravenously for 5 days every three weeks in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes: a phase II study

M. Sanmamed, J. Berros, J. Viéitez, 2011, Investigational New Drugs.

Phase II study of oral ftorafur and uracil in patients with advanced renal cell carcinoma.

E. Esteban, J. Cueva, Y. Fernández, 1993, European journal of cancer.

Combination of Docetaxel, Epirubicin and Vinorelbine Administered Every 2 Weeks as First-line Therapy in Patients with Metastatic Breast Cancer: A Dose-finding Study

E. Esteban, J. Viéitez, Y. Fernández, 2003, Breast Cancer Research and Treatment.